OBJECTIVES: The aim of the present study was to evaluate the ability of head-shaking nystagmus (HSNy), evoked after the resolution of a vertigo spell, to predict an imminent crisis in the early stage of Meniere's disease (MD). MATERIALS AND METHODS: A total of 20 patients in the early stage of MD were included in the study. The head-shaking test (HST) was performed twice, during the first visit within 24 h of vertigo spell (T0) and 48 h later (T1). The onset of a new vertigo episode during the 2 weeks following the first visit was recorded in each patient's medical record. The sensitivity and specificity of HSNy toward predicting a new vertigo episode were calculated. RESULTS: At T0, an evoked ipsilesional HSNy in 15 (75%) patients was observed; in four of them, the HSNy had a biphasic component. The HSNy was present and persistent at T1 in 8 (42.1%) patients; among these cases, 6 patients had ipsilesional HSNy, and 2 patients a contralesional HSNy. None of the patients presented with a biphasic HSNy at T1. Seven (36.8%) patients experienced the recurrence of a vertigo crisis. Among these, 6 patients had ipsilesional HSNy at T1. Only 8 patients with ipsilesional HSNy at T0 did not have recurrence. The sensitivity of the ipsilesional HSNy in predicting the recurrence of vertigo in patients with MD was 100% at T0 and 85.7% at T1. The specificity was 46.6% and 100% at T0 and T1, respectively. CONCLUSION: The HST can be a useful test in the early stages of MD to predict a new vertigo attack.
OBJECTIVES: The aim of the present study was to evaluate the ability of head-shaking nystagmus (HSNy), evoked after the resolution of a vertigo spell, to predict an imminent crisis in the early stage of Meniere's disease (MD). MATERIALS AND METHODS: A total of 20 patients in the early stage of MD were included in the study. The head-shaking test (HST) was performed twice, during the first visit within 24 h of vertigo spell (T0) and 48 h later (T1). The onset of a new vertigo episode during the 2 weeks following the first visit was recorded in each patient's medical record. The sensitivity and specificity of HSNy toward predicting a new vertigo episode were calculated. RESULTS: At T0, an evoked ipsilesional HSNy in 15 (75%) patients was observed; in four of them, the HSNy had a biphasic component. The HSNy was present and persistent at T1 in 8 (42.1%) patients; among these cases, 6 patients had ipsilesional HSNy, and 2 patients a contralesional HSNy. None of the patients presented with a biphasic HSNy at T1. Seven (36.8%) patients experienced the recurrence of a vertigo crisis. Among these, 6 patients had ipsilesional HSNy at T1. Only 8 patients with ipsilesional HSNy at T0 did not have recurrence. The sensitivity of the ipsilesional HSNy in predicting the recurrence of vertigo in patients with MD was 100% at T0 and 85.7% at T1. The specificity was 46.6% and 100% at T0 and T1, respectively. CONCLUSION: The HST can be a useful test in the early stages of MD to predict a new vertigo attack.
Authors: José A Lopez-Escamez; John Carey; Won-Ho Chung; Joel A Goebel; Måns Magnusson; Marco Mandalà; David E Newman-Toker; Michael Strupp; Mamoru Suzuki; Franco Trabalzini; Alexandre Bisdorff Journal: Acta Otorrinolaringol Esp Date: 2015-08-12
Authors: Tsutomu Nakashima; Ilmari Pyykkö; Megan A Arroll; Margaretha L Casselbrant; Carol A Foster; Nauman F Manzoor; Cliff A Megerian; Shinji Naganawa; Yi-Ho Young Journal: Nat Rev Dis Primers Date: 2016-05-12 Impact factor: 52.329
Authors: L Frejo; E Martin-Sanz; R Teggi; G Trinidad; A Soto-Varela; S Santos-Perez; R Manrique; N Perez; I Aran; M S Almeida-Branco; A Batuecas-Caletrio; J Fraile; J M Espinosa-Sanchez; V Perez-Guillen; H Perez-Garrigues; M Oliva-Dominguez; O Aleman; J Benitez; P Perez; J A Lopez-Escamez Journal: Clin Otolaryngol Date: 2017-02-26 Impact factor: 2.597
Authors: Paz Pérez; José Luis Llorente; Justo R Gómez; Alfredo Del Campo; Aurora López; Carlos Suárez Journal: Laryngoscope Date: 2004-06 Impact factor: 3.325
Authors: Massimo Ralli; Vittorio D'Aguanno; Arianna Di Stadio; Armando De Virgilio; Adelchi Croce; Lucia Longo; Antonio Greco; Marco de Vincentiis Journal: J Immunol Res Date: 2018-08-19 Impact factor: 4.818